GO-COLITIS Trial in Ulcerative Colitis Patients Shows Simponi Induces Positive Clinical Response

GO-COLITIS Trial in Ulcerative Colitis Patients Shows Simponi Induces Positive Clinical Response
Janssen Pharmaceutical's Simponi (golimumab) induced a clinical response in more than two-thirds of patients with moderate to severe ulcerative colitis in the induction phase of the GO-COLITIS clinical trial, according to the study “Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study (DOP049),” recently presented at the European Crohn’s and Colitis Organization’s (ECCO) Congress in Amsterdam. Simponi “is a human monoclonal antibody that forms high-affinity, stable complexes with both the soluble and transmembrane bioactive forms of human tumor necrosis factor (TNF)-alpha,” as described in a news release. “We are delighted to be able to contribute real-world data to the growing clinical experience with golimumab,” Chris Probert, M.D., of the University of Liverpool, said in the release. “This response rate shows the potential efficacy of golimumab in the management of moderate to severely active ulcerative colitis.” The phase 4, multicenter, open-label, single-arm GO-COLITIS (
Subscribe or to access all post and page content.